Insider · CIK 0001991787

Bala Mohan

Reports to the SEC for 1 company · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001991787

Forms 4 and 5

Insider transactions

38 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-01-06	MRSNMersana Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	SVP, Chief Development	DDisposition to Issuer	−1,853 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	SVP, Chief Development	DDisposition to Issuer	−3,515 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	SVP, Chief Development	DDisposition to Issuer	−7,734 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc.U Disposition from Tender	SVP, Chief Development	UDisposition from Tender	−2,927 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitsD Disposition to Issuer	SVP, Chief Development	DDisposition to Issuer	−2,500 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitsD Disposition to Issuer	SVP, Chief Development	DDisposition to Issuer	−1,750 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitsD Disposition to Issuer	SVP, Chief Development	DDisposition to Issuer	−700 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	SVP, Chief Development	DDisposition to Issuer	−9,309 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	SVP, Chief Development	DDisposition to Issuer	−1,190 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	SVP, Chief Development	DDisposition to Issuer	−5,246 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	SVP, Chief Development	DDisposition to Issuer	−1,053 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	SVP, Chief Development	DDisposition to Issuer	−2,646 sh	—	—	0
2025-10-27	MRSNMersana Therapeutics, Inc.S Sale	SVP, Chief Development	SSale	−77 sh	$9.90	−$762.3	2,922
2025-10-25	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	SVP, Chief Development	MExercise/Conversion	−250 sh	—	—	0
2025-10-25	MRSNMersana Therapeutics, Inc.M Exercise/Conversion	SVP, Chief Development	MExercise/Conversion	+250 sh	—	—	2,999
2025-01-16	MRSNMersana Therapeutics, Inc.S Sale	SVP, Chief Development	SSale	−5,939 sh	$0.58	−$3,444.62	68,872
2025-01-15	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitA Award	SVP, Chief Development	AAward	+62.5K sh	—	—	62,500
2025-01-15	MRSNMersana Therapeutics, Inc.M Exercise/Conversion	SVP, Chief Development	MExercise/Conversion	+14.6K sh	—	—	74,811
2025-01-15	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	SVP, Chief Development	MExercise/Conversion	−14.6K sh	—	—	43,750
2025-01-15	MRSNMersana Therapeutics, Inc. · Stock Option (Right to Buy)A Award	SVP, Chief Development	AAward	+281K sh	—	—	281,250
2025-01-14	MRSNMersana Therapeutics, Inc.S Sale	SVP, Chief Development	SSale	−3,253 sh	$0.66	−$2,146.98	60,228
2025-01-13	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	SVP, Chief Development	MExercise/Conversion	−8,750 sh	—	—	17,500
2025-01-13	MRSNMersana Therapeutics, Inc.M Exercise/Conversion	SVP, Chief Development	MExercise/Conversion	+8,750 sh	—	—	63,481
2024-10-28	MRSNMersana Therapeutics, Inc.S Sale	SVP, Chief Development	SSale	−1,884 sh	$1.90	−$3,579.6	54,731
2024-10-25	MRSNMersana Therapeutics, Inc.M Exercise/Conversion	SVP, Chief Development	MExercise/Conversion	+6,250 sh	—	—	56,615
2024-10-25	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	SVP, Chief Development	MExercise/Conversion	−6,250 sh	—	—	6,250
2024-10-03	MRSNMersana Therapeutics, Inc.S Sale	SVP, Chief Development	SSale	−5,598 sh	$1.96	−$11K	50,365
2024-10-02	MRSNMersana Therapeutics, Inc.S Sale	SVP, Chief Development	SSale	−8,089 sh	$2.00	−$16.2K	55,963
2024-10-01	MRSNMersana Therapeutics, Inc.M Exercise/Conversion	SVP, Chief Development	MExercise/Conversion	+50K sh	—	—	64,052
2024-10-01	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	SVP, Chief Development	MExercise/Conversion	−50K sh	—	—	0
2024-01-16	MRSNMersana Therapeutics, Inc.S Sale	SVP, Chief Development	SSale	−3,431 sh	$2.71	−$9,298.01	14,052
2024-01-15	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitA Award	SVP, Chief Development	AAward	+58.3K sh	—	—	58,333
2024-01-15	MRSNMersana Therapeutics, Inc. · Stock Option (Right to Buy)A Award	SVP, Chief Development	AAward	+263K sh	—	—	262,500
2024-01-13	MRSNMersana Therapeutics, Inc.M Exercise/Conversion	SVP, Chief Development	MExercise/Conversion	+8,750 sh	—	—	17,483
2024-01-13	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	SVP, Chief Development	MExercise/Conversion	−8,750 sh	—	—	26,250
2023-10-26	MRSNMersana Therapeutics, Inc.S Sale	SVP, Chief Development	SSale	−1,912 sh	$1.13	−$2,160.56	8,733
2023-10-25	MRSNMersana Therapeutics, Inc.M Exercise/Conversion	SVP, Chief Development	MExercise/Conversion	+6,250 sh	—	—	10,645
2023-10-25	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	SVP, Chief Development	MExercise/Conversion	−6,250 sh	—	—	12,500

Recent filings

Accepted (ET)
Jan 64
Bala Mohan0001104659-26-001379
SEC(opens sec.gov)
Oct 284
Bala Mohan0001104659-25-103170
SEC(opens sec.gov)
Jan 174
Bala Mohan0001104659-25-004590
SEC(opens sec.gov)

Companies

Mersana Therapeutics, Inc.SVP, Chief DevelopmentMRSN

Address

C/O MERSANA THERAPEUTICS, INC. 840 MEMORIAL DRIVE

CAMBRIDGE, MA, 02139